Actinium Pharmaceuticals Inc (ATNM)

[BooDog]

Actinium Pharmaceuticals Announces Appointment of Hematology Expert Dr. Richard Stone of the Dana-Farber Cancer Institute to its Scientific Advisory Board


May 17, 2017
•Dr. Stone is a world renowned physician with extensive research and clinical experience focused on refractory leukemia patients and advanced myeloproliferative disorders


•Actinium’s Scientific Advisory Board contributes to the development of Iomab-B, Actinium’s Phase 3 drug candidate intended to facilitate bone marrow transplants

NEW YORK, May 17, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that Dr. Richard Stone, Chief of Staff and Program Director, Acute Leukemia at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School has joined the Company’s Scientific Advisory Board (SAB). Actinium’s SAB is comprised of independent physicians considered to be key opinion leaders (KOLs) in the field of hematology and bone marrow transplant that contribute to and advise Actinium on the development of Iomab-B. Iomab-B is Actinium’s lead asset that is in a pivotal Phase 3 clinical trial that, upon approval, is intended to be an induction and conditioning agent prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) who are over the age of 55. The pivotal Phase 3 Iomab-B SIERRA clinical trial is currently enrolling patients at many of the leading bone marrow transplant centers in the U.S.



http://ir.actiniumpharma.com/press-releases/detail/228/actinium-pharmaceuticals-announces-appointment-of

Very interesting indeed. Bring on the bull/bear battle.

I'll be taking some nibbles.